US 2014/0350040 A1Published application

2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4] nonane- 6 -one compound as voltage-gated sodium channels modulator

AssigneeConvergence Pharmaceuticals Limited

InventorsDavid R. Witty, David T. MacPherson, Gerard M.P. Giblin, Steven J. Stanway

Life of this patent

Estimating the term…

Abstract

The invention relates to spiro derivative of formula (I), to the use of said derivative in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivative and processes for its preparation.

Claims11

Dependent claims

A compound of formula (I) which is 7-methyl-2-[4-[3-(trifluoromethoxy)phenyl]-2-pyridyl]-1,7-diazaspiro[4.4]nonan-6-one:

or a pharmaceutically acceptable salt or solvate thereof.

Dependencies are inferred from the claim text.

Facts

Application: 14/365,391Filed 21 Dec 2012
Priority: GB 1122113.222 Dec 2011
Published: 27 Nov 2014
Term ends: Not estimatedThe source records don’t support an estimate.

Classification24 codes

C07D 401/14
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a…:…
A61P 3/00
Drugs for disorders of the metabolism
A61P 13/10
Drugs for disorders of the urinary system: of the bladder
A61P 19/02
Drugs for skeletal disorders: for joint disorders, e.g. arthritis, arthrosis

Family

Application61/579,613Us provisional application · filed 22 Dec 2011
US 9,303,032 B2Related patent
US 2014/0350040 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results